A public-private consortium formed to investigate multi-drug resistance in malaria this week reached the end of a five-year, €2.8 million (about $3.6 million) project having identified a number of genetic markers related to drug resistance and developed a highly sensitive and specific direct-from-blood, lateral flow strip-based PCR assay for Plasmodium, the family of parasites that causes the disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.